Freedom Together Foundation Has $6.85 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Freedom Together Foundation cut its holdings in Eli Lilly and Company (NYSE:LLY) by 79.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,868 shares of the company’s stock after selling 35,000 shares during the quarter. Eli Lilly and Company comprises about 0.8% of Freedom Together Foundation’s investment portfolio, making the stock its 4th biggest holding. Freedom Together Foundation’s holdings in Eli Lilly and Company were worth $6,846,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of LLY. Watts Gwilliam & Co. LLC boosted its stake in shares of Eli Lilly and Company by 6.0% during the 4th quarter. Watts Gwilliam & Co. LLC now owns 1,688 shares of the company’s stock worth $1,306,000 after acquiring an additional 96 shares in the last quarter. Baker Tilly Wealth Management LLC lifted its holdings in shares of Eli Lilly and Company by 20.9% during the fourth quarter. Baker Tilly Wealth Management LLC now owns 1,367 shares of the company’s stock valued at $1,055,000 after purchasing an additional 236 shares during the last quarter. ORG Partners LLC boosted its position in shares of Eli Lilly and Company by 34.3% in the 4th quarter. ORG Partners LLC now owns 1,556 shares of the company’s stock valued at $1,202,000 after purchasing an additional 397 shares during the period. ORG Wealth Partners LLC increased its stake in Eli Lilly and Company by 21.7% in the 4th quarter. ORG Wealth Partners LLC now owns 1,630 shares of the company’s stock worth $1,258,000 after purchasing an additional 291 shares in the last quarter. Finally, Harbor Capital Advisors Inc. raised its holdings in Eli Lilly and Company by 0.6% during the 4th quarter. Harbor Capital Advisors Inc. now owns 15,056 shares of the company’s stock worth $11,623,000 after buying an additional 92 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY opened at $736.21 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The stock’s 50 day moving average price is $810.98 and its two-hundred day moving average price is $811.52. The firm has a market capitalization of $697.73 billion, a P/E ratio of 62.87, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same quarter in the previous year, the business posted $2.58 EPS. The company’s revenue was up 45.2% on a year-over-year basis. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.81%. Eli Lilly and Company’s dividend payout ratio is 48.82%.

Analyst Ratings Changes

Several research firms have weighed in on LLY. Truist Financial lifted their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research note on Friday, January 17th. The Goldman Sachs Group raised Eli Lilly and Company from a “neutral” rating to a “buy” rating and cut their price target for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a research note on Thursday, January 16th. Finally, Hsbc Global Res downgraded Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. One analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,002.80.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.